RxDoctor Payments Data

Atilla Kayalar, MD

Cardiovascular Disease · Queensbury, NYNPI 1518958610

Payments from drug & device makers

$3,078in general payments, 2019–2025

Across 47 payments — averaging $65.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Cvrx, Inc.$231
  • Baxter Healthcare$202
  • Edwards Lifesciences$130
  • Novartis$120
  • E.r. Squibb & Sons, L.L.C.$98
  • plus $324 from 11 others

What the payments were for

  • Travel & lodging$1,79558%
  • Food & beverage$1,27141%
  • Education$120%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,078 in reported general payments places this provider in the 60th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$100,092
Medicare patients
1,372
Services billed
2,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban505$584,188
EntrestoSacubitril/Valsartan65$110,515
XareltoRivaroxaban82$105,482
MultaqDronedarone Hcl51$79,314
BrilintaTicagrelor24$28,206
Repatha SureclickEvolocumab18$26,837
JardianceEmpagliflozin14$19,037
Metoprolol Succinate645$9,712
Ranolazine ErRanolazine100$8,399
Nifedipine ErNifedipine193$5,539
Ezetimibe139$5,096
Rosuvastatin Calcium345$5,095
Atorvastatin Calcium491$4,895
Nebivolol Hcl48$3,959
Isosorbide Mononitrate ErIsosorbide Mononitrate234$3,534

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$584,188505 claims
NovartisEntresto$120$110,51565 claims
Johnson & JohnsonXarelto$47$105,48282 claims
Boehringer IngelheimJardiance$19$19,03714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Queensbury

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →